Cargando…
Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until recently, there were limited therapeutic options. However, over the last decade our understanding of the molecular foundation of thyroid function and carcinogenesis has driven the development of many novel...
Autores principales: | Fullmer, Tanner, Cabanillas, Maria E., Zafereo, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321684/ https://www.ncbi.nlm.nih.gov/pubmed/34335481 http://dx.doi.org/10.3389/fendo.2021.720723 |
Ejemplares similares
-
Radioactive iodine in low- to intermediate-risk papillary thyroid cancer
por: Zhao, Hengqiang, et al.
Publicado: (2022) -
The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023) -
Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer
por: Liu, Lina, et al.
Publicado: (2022) -
Re-treatment With Adjuvant Radioactive Iodine Does Not Improve Recurrence-Free Survival of Patients With Differentiated Thyroid Cancer
por: Bouvet, Clément, et al.
Publicado: (2019) -
Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score–matched analysis
por: Guo, Honghao, et al.
Publicado: (2023)